---
title: "吉利德科学为其最大创收产品取得了 ‘稳固的胜利’，股价随之上涨"
description: "吉利德科学的股票在周一上涨，此前这家生物技术巨头表示已与三家仿制药制造商达成协议，以推迟它们的 Biktarvy 仿制药的上市"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260073982.md"
published_at: "2025-10-06T15:38:10.000Z"
---

# 吉利德科学为其最大创收产品取得了 ‘稳固的胜利’，股价随之上涨

> 吉利德科学的股票在周一上涨，此前这家生物技术巨头表示已与三家仿制药制造商达成协议，以推迟它们的 Biktarvy 仿制药的上市

Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats.

### Related Stocks

- [GILD.US - 吉利德科学](https://longbridge.com/zh-CN/quote/GILD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Peering Into Gilead Sciences Inc's Recent Short Interest | Gilead Sciences Inc's short interest has increased by 3.24%, with 23.68 million shares sold short, representing 1.91% of | [Link](https://longbridge.com/zh-CN/news/276365010.md) |
| Gilead Sciences (NASDAQ:GILD) Updates FY 2026 Earnings Guidance | Gilead Sciences (NASDAQ:GILD) has updated its FY 2026 earnings guidance, projecting EPS between 8.450-8.850, slightly be | [Link](https://longbridge.com/zh-CN/news/275527709.md) |
| 13 Analysts Have This To Say About Teva Pharmaceutical Indus | Teva Pharmaceutical Industries (NYSE:TEVA) was analyzed by 13 analysts, revealing a mix of bullish and bearish sentiment | [Link](https://longbridge.com/zh-CN/news/276269936.md) |
| NRx Pharmaceuticals Establishes $20 Million ATM Stock Program | NRx Pharmaceuticals has established a $20 million at-the-market stock program, filing a prospectus supplement under an e | [Link](https://longbridge.com/zh-CN/news/276160986.md) |
| Zoetis challenged to return to growth | Zoetis experienced a modest revenue growth of 2% in 2025, the lowest in a decade, primarily due to a 14% decline in its  | [Link](https://longbridge.com/zh-CN/news/276048923.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。